A detailed history of Financial Enhancement Group LLC transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Financial Enhancement Group LLC holds 10,000 shares of IBRX stock, worth $25,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,000
Holding current value
$25,000
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Jul 14, 2025

BUY
$1.89 - $3.44 $18,900 - $34,400
10,000 New
10,000 $26,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Financial Enhancement Group LLC Portfolio

Follow Financial Enhancement Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Financial Enhancement Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Financial Enhancement Group LLC with notifications on news.